Total Returns (Price + Dividend) 
Hikma Pharmaceuticals Plc for the last several years.
Risk Adjusted Returns v/s 
News

Hikma Pharmaceuticals Hits Day Low of GBP 15.22 Amid Price Pressure
Hikma Pharmaceuticals Plc has faced notable stock volatility, hitting an intraday low and experiencing significant declines over various timeframes. Despite maintaining high management efficiency and a low debt-to-equity ratio, the company is challenged by rising raw material costs and a substantial drop in pre-tax profit.
Read More
Hikma Pharmaceuticals Hits Day High with Strong 6.66% Intraday Surge
Hikma Pharmaceuticals Plc has seen a significant rise in its stock price today, contrasting with the modest gains of the FTSE 100. Despite recent improvements, the company's year-to-date performance remains negative, and it faces challenges such as rising raw material costs and a decline in pre-tax profits.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 1 Foreign Institutions (0.0%)
Annual Results Snapshot (Consolidated) - Dec'23
YoY Growth in year ended Dec 2023 is 13.19% vs 10.08% in Dec 2022
YoY Growth in year ended Dec 2023 is -0.39% vs -49.21% in Dec 2022






